{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:38:12Z","timestamp":1768207092993,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    Invasive mucormycosis (IM) in pediatric patients is a rare but life-threatening fungal disease with limited treatment options. Isavuconazole is a new triazole that has shown efficacy and safety in adults for both primary and salvage treatment of mucormycosis. However, data regarding the initial use of isavuconazole in children are rare. In this study, we report a case of a 6-year-old girl with diabetes mellitus. Metagenomic next-generation sequencing detected\n                    <jats:italic>Rhizopus oryzae<\/jats:italic>\n                    in her bronchoalveolar lavage fluid , and a chest computed tomography revealed a reversed halo sign. Oral isavuconazole was given as primary monotherapy with continuous control of blood glucose. After the lesion partially shrank and became confined, the patient visited the thoracic surgery department to undergo lobectomy; she recovered well after the procedure. This report highlights the importance of quick diagnosis of mucormycosis and may provide a reference for providing the initial antifungal treatment in pediatric mucormycosis. All of the aforementioned interventions helped buy time for subsequent surgical treatment, leading to the curing of the child. Isavuconazole may represent an effective and safe therapeutic option as first-line monotherapy for pediatric mucormycosis.\n                  <\/jats:p>","DOI":"10.3389\/fped.2025.1701905","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:42:13Z","timestamp":1768196533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Isavuconazole as initial antifungal therapy combined with surgical management of pediatric pulmonary mucormycosis: a case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Yao","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianjiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shichao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jpids\/pix107","article-title":"Mucormycosis in children: review and recommendations for management","volume":"7","author":"Francis","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/CLEP.S12502","article-title":"Epidemiology and treatment approaches in management of invasive fungal infections","volume":"3","author":"Kriengkauykiat","year":"2011","journal-title":"Clin Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s12879-016-2005-1","article-title":"Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries","volume":"16","author":"Pana","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11046-021-00607-4","article-title":"Mucormycosis in mainland China: a systematic review of case reports","volume":"187","author":"Wei","year":"2022","journal-title":"Mycopathologia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"844880","DOI":"10.3389\/fmed.2022.844880","article-title":"How to treat a child with a concurrent diagnosis of leukemia and generalized mucormycosis? Case report","volume":"9","author":"Sosnowska-Sienkiewicz","year":"2022","journal-title":"Front. Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11046-018-0287-0","article-title":"Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: a case report and review of the literature","volume":"184","author":"Pomorska","year":"2019","journal-title":"Mycopathologia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1368165","DOI":"10.3389\/fcimb.2024.1368165","article-title":"Clinical features of pediatric mucormycosis: role of metagenomic next generation sequencing in diagnosis","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jemermed.2021.07.024","article-title":"New-onset pediatric diabetes complicated by diabetic ketoacidosis and invasive rhinocerebral mucormycosis with internal carotid artery occlusion","volume":"62","author":"Mahan","year":"2022","journal-title":"J Emerg Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e01783","DOI":"10.1128\/AAC.01783-19","article-title":"A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation","volume":"64","author":"Decembrino","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40360-018-0273-7","article-title":"Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report","volume":"19","author":"Cornu","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.5863\/1551-6776-26.8.863","article-title":"Isavuconazonium sulfate use in multi-modal management of invasive mucormycosis in four pediatric allogeneic hematopoietic cell transplant patients","volume":"26","author":"Ferdjallah","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1172\/JCI71349","article-title":"Coth3 mediates fungal invasion of host cells during mucormycosis","volume":"124","author":"Gebremariam","year":"2014","journal-title":"J. Clin. Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients","volume":"39","author":"Ashkenazi-Hoffnung","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e00290","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e00484","DOI":"10.1128\/aac.00484-24","article-title":"Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial","volume":"68","author":"Segers","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e02032","DOI":"10.1128\/AAC.02032-20","article-title":"A physiologically based pharmacokinetic analysis to predict the pharmacokinetics of intravenous isavuconazole in patients with or without hepatic impairment","volume":"65","author":"Huang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1086\/521245","article-title":"The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients","volume":"45","author":"Lass-Florl","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/coa.13175","article-title":"A meta-analysis of survival factors in rhino-orbital-cerebral mucormycosis\u2014has anything changed in the past 20 years?","volume":"43","author":"Vaughan","year":"2018","journal-title":"Clin Otolaryngol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure\u2013response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/IDR.S81416","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Thompson","year":"2016","journal-title":"Infect Drug Resist"},{"key":"B24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1701905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:42:19Z","timestamp":1768196539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1701905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":24,"alternative-id":["10.3389\/fped.2025.1701905"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1701905","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1701905"}}